Drug Trial Radar · NCT06779097
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,564
Planned (sponsor's estimate)
Start
Feb 2025
Primary completion
Mar 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis who have converted from other biologics. To explore the efficacy of difficult-to-treat area, patient satisfaction and patient-reported outcomes (PRO).
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
Vunakizumab (IL-17A inhibitor)Drug
Vunakizumab (IL-17A inhibitor)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who achieved at least a 90% improvement from baseline in PASI scores by week 12 (PASI 90).Time frame: Three months
- Proportion of subjects achieving sPGA 0/1 response at week 12.Time frame: Three months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.